Compare GENC & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GENC | ELTX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.5M | 185.4M |
| IPO Year | 1995 | 2014 |
| Metric | GENC | ELTX |
|---|---|---|
| Price | $15.94 | $3.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $17.60 | ★ $18.00 |
| AVG Volume (30 Days) | 28.8K | ★ 4.0M |
| Earning Date | 02-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.08 | ★ 39.29 |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $48,943,000.00 | $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.51 | N/A |
| P/E Ratio | $32.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.22 | $2.66 |
| 52 Week High | $17.40 | $16.00 |
| Indicator | GENC | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.02 | 36.12 |
| Support Level | $14.55 | $2.72 |
| Resistance Level | $16.47 | $9.76 |
| Average True Range (ATR) | 0.44 | 0.46 |
| MACD | 0.10 | 0.20 |
| Stochastic Oscillator | 57.11 | 13.79 |
Gencor Industries Inc and its subsidiaries are a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company's products are manufactured in the United States and sold through a combination of Company sales representatives and independent dealers and agents. The Company has one reporting segment, equipment for the highway construction industry. The Company's principal core products include asphalt pavers, hot mix asphalt plants, combustion systems, and fluid heat transfer systems. It operates in the United States, Canada, and other foreign countries, with the majority of revenue coming from the United States.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.